Australian researchers comparing Retatrutide vs Semaglutide should understand the key mechanistic differences between these two GLP-1 class research compounds.
Semaglutide is a GLP-1 receptor agonist, activating a single metabolic pathway. It has been extensively studied and is one of the most established compounds in the GLP-1 class.
Retatrutide activates three receptors — GLP-1, GIP and glucagon — making it mechanistically distinct from Semaglutide. This triple-agonist profile is unique among currently studied GLP-1 class compounds.
Researchers studying comprehensive metabolic pathways increasingly favour Retatrutide due to its broader receptor activity. Both compounds remain available through GLP1 Peptides Australia with fast Australia-wide delivery.